<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Clomifene</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00882</strong>&#160; (APRD00880)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00882/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00882/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00882.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00882.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00882.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00882.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00882.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00882">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Clomifeno</td><td>Spanish</td><td>INN</td></tr><tr><td>Clomifenum</td><td>Latin</td><td>INN</td></tr><tr><td>Clomiphene</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Clomifene citrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000490/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000490/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: PYTMYKVIJXPNBD-OQKDUQJOSA-N</li>
              <li>Monoisotopic Mass: 597.21294484</li>
              <li>Average Mass: 598.083</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000490">DBSALT000490</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Androxal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Clomid</td><td>Sanofi-Aventis</td></tr><tr><td>Clomifert</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Clostilbegyt</td><td>Egis</td></tr><tr><td>Omifin</td><td>Sanofi</td></tr><tr><td>Serophene</td><td>AstraZeneca</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/fertility-agents-female">Fertility Agents, Female</a></li>
<li><a href="/mesh/estrogen-antagonists">Estrogen Antagonists</a></li>
<li><a href="/mesh/selective-estrogen-receptor-modulators">Selective Estrogen Receptor Modulators</a></li></ul></td></tr><tr><th>CAS number</th><td>911-45-5</td></tr><tr><th>Weight</th><td>Average: 405.96<br>Monoisotopic: 405.18594223</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>28</sub>ClNO</td></tr><tr><th>InChI Key</th><td>GKIRPKYJQBWNGO-OCEACIFDSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">{2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]ethyl}diethylamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Stilbenes</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Stilbenes</td></tr><tr><th>Alternative parents</th><td>Diphenylmethanes; Phenylpropenes; Phenol Ethers; Alkyl Aryl Ethers; Tertiary Amines; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>phenylpropene; phenol ether; alkyl aryl ether; benzene; tertiary amine; polyamine; ether; organohalogen; organochloride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups  to a phenyl ring lead to stilbenoids.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation. </td></tr><tr><th>Pharmacodynamics</th><td>Clomifene (previously clomiphene) is an orally administered, non steroidal, ovulatory stimulant that acts as a selective estrogen receptor modulator (SERM). Clomifene can lead to multiple ovulation, and hence increase the risk of conceiving twins. In comparison to purified FSH, the rate of ovarian hyperstimulation syndrome is low. There may be an increased risk of ovarian cancer and weight gain. Clomifene is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomifene initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event, in response to a course of clomifene therapy, is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.</td></tr><tr><th>Mechanism of action</th><td>Clomifene has both estrogenic and anti-estrogenic properties, but its precise mechanism of action has not been determined. Clomifene appears to stumulate the release of gonadotropins, follicle-stimulating hormone (FSH), and leuteinizing hormone (LH), which leads to the development and maturation of ovarian follicle, ovulation, and subsequent development and function of the coprus luteum, thus resulting in pregnancy. Gonadotropin release may result from direct stimulation of the hypothalamic-pituitary axis or from a decreased inhibitory influence of estrogens on the hypothalamic-pituitary axis by competing with the endogenous estrogens of the uterus, pituitary, or hypothalamus. Clomifene has no apparent progestational, androgenic, or antrandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function.</td></tr><tr><th>Absorption</th><td>Based on early studies with 14 C-labeled clomifene, the drug was shown to be readily absorbed orally in humans.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td>Based on early studies with 14C-labeled clomiphene citrate, the drug was shown to be readily absorbed orally in humans and excreted principally in the feces.
Mean urinary excretion was approximately 8% with fecal excretion of about 42%.</td></tr><tr><th>Half life</th><td>5-7 days</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The acute oral LD<sub>50</sub> of clomifene is 1700 mg/kg in mice and 5750 mg/kg in rats. The toxic dose in humans is not known. Toxic effects accompanying acute overdosage of clomifene have not been reported. Signs and symptoms of overdosage as a result of the use of more than the recommended dose during clomifene therapy include nausea, vomiting, vasomotor flushes, visual blurring, spots or flashes, scotomata, ovarian enlargement with pelvic or abdominal pain.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8723</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7235</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7536</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7799</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6476</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7021</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7972</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6847</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7021</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9332</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6036</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8315</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.7004</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8089</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9254</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.621
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9895
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8805 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.8038
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8672
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>Par pharmaceutical inc</li>
<li>Milex products inc</li>
<li>Emd serono inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.emdcanada.com">EMD Canada Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Merrell Pharmaceuticals Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>ClomiPHENE Citrate 30 50 mg tablet Box</td><td>215.9USD</td><td>box</td></tr><tr><td>Clomiphene citrate powder</td><td>47.74USD</td><td>g</td></tr><tr><td>Clomid 50 mg tablet</td><td>17.1USD</td><td>tablet</td></tr><tr><td>Serophene 50 mg tablet</td><td>11.08USD</td><td>tablet</td></tr><tr><td>Clomiphene citrate 50 mg tab</td><td>6.86USD</td><td>tablet</td></tr><tr><td>Clomid 50 mg Tablet</td><td>6.09USD</td><td>tablet</td></tr><tr><td>Serophene 50 mg Tablet</td><td>5.52USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>116.5-118</td><td>Allen, R.E., Palopoli, F.P., Schumann, E.L. and Van Carnpen, M.G. Jr.; US. Patent 2,914,563; November 24, 1959; assigned to The Wrn. S. Merrell Company.</td></tr><tr><td>water solubility</td><td>Slightly soluble</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>7.2</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.14e-04 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>6.08</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>6.47</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-6</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>9.31</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>12.47</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>9</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>133.76</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>46.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Allen, R.E., Palopoli, F.P., Schumann, E.L. and Van Carnpen, M.G. Jr.; US. Patent 2,914,563; November 24, 1959; assigned to The Wrn. S. Merrell Company.</p></span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Purvin VA: Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol. 1995 Apr;113(4):482-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7710399">Pubmed</a></li>
	<li>Hayon T, Atlas L, Levy E, Dvilansky A, Shpilberg O, Nathan I: Multifactorial activities of nonsteroidal antiestrogens against leukemia. Cancer Detect Prev. 2003;27(5):389-96. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14585326">Pubmed</a></li>
	<li>Fritz MA, Holmes RT, Keenan EJ: Effect of clomiphene citrate treatment on endometrial estrogen and progesterone receptor induction in women. Am J Obstet Gynecol. 1991 Jul;165(1):177-85. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1906682">Pubmed</a></li>
	<li>Hughes E, Brown J, Collins JJ, Vanderkerchove P: Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000057. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20091498">Pubmed</a></li>
	<li>Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E: Clomiphene and anti-oestrogens for ovulation induction in <span class="caps">PCOS</span>. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD002249. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19821295">Pubmed</a></li>
	<li>Use of clomiphene citrate in women. Fertil Steril. 2006 Nov;86(5 Suppl 1):S187-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17055820">Pubmed</a></li>
	<li>Homburg R: Oral agents for ovulation induction&#8212;clomiphene citrate versus aromatase inhibitors. Hum Fertil (Camb). 2008 Mar;11(1):17-22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18320435">Pubmed</a></li>
	<li>Homburg R: Clomiphene citrate&#8212;end of an era? A mini-review. Hum Reprod. 2005 Aug;20(8):2043-51. Epub 2005 May 5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15878925">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00962" target="_blank">D00962 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C06917" target="_blank">C06917 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50170640" target="_blank">50170640 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=3752" target="_blank">3752 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1200667" target="_blank">CHEMBL1200667 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001013" target="_blank">DAP001013 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449046" target="_blank">PA449046 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=640158" target="_blank">640158 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/clomiph.htm" target="_blank">http://www.rxlist.com/cgi/generic/clomiph.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/clo1088.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/clo1088.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Clomifene" target="_blank">Clomifene <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>G03GB02<ul class="atc-drug-tree"><li><a href="/atc/G#G">G &#8212; GENITO URINARY SYSTEM AND SEX HORMONES</a></li><li><a href="/atc/G03#G03">G03 &#8212; SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</a></li><li><a href="/atc/G03G#G03G">G03G &#8212; GONADOTROPINS AND OTHER OVULATION STIMULANTS</a></li><li><a href="/atc/G03GB#G03GB">G03GB &#8212; Ovulation stimulants, synthetic</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>68:16.12</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>The enzyme inducer, amobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01352">Aprobarbital</a></td><td>The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>The enzyme inducer, butabarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>The enzyme inducer, butalbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01353">Butethal</a></td><td>The enzyme inducer, butethal, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The enzyme inducer, ethotoin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01354">Heptabarbital</a></td><td>The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01355">Hexobarbital</a></td><td>The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>The enzyme inducer, methohexital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00849">Methylphenobarbital</a></td><td>The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The estrogenic agent, clomifene, may increase the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The enzyme inducer, primidone, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00481">Raloxifene</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>The enzyme inducer, secobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00306">Talbutal</a></td><td>The enzyme inducer, talbutal, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01586">Ursodeoxycholic acid</a></td><td>Estrogens decreases the effect of ursodiol</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>